anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a hair cosmetic composition which can obtain a sufficient hair-dyeing force and a sufficient hair-bleaching force and can obtain sufficient storage stability.  &lt;P&gt;SOLUTION: This hair cosmetic composition which comprises the first agent comprising an alkanolamine, an oily component, a surfactant, at least one of water and water-soluble solvents and a dye, and the second agent comprising an oxidizing agent and water, is characterized in that the first agent is a water-in-oil type solubilized product or a water-soluble solvent-in-oil type solubilized product and that the first agent is mixed with the second agent to form the oil-in-water type emulsion. The second agent is preferably an aqueous solution, and the second agent preferably further contains a thickener. The first agent and the second agent of the hair cosmetic composition are mixed with each other when used, and used as an oxidation hair dye. Or, the first agent and the second agent of the hair cosmetic composition are mixed with each other when used, and used as a hair-bleaching agent.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new vaccine for curing mycobacteria infection, especially tuberculosis.  &lt;P&gt;SOLUTION: The invention relates to a methylated immunogenic recombination peptide sequence containing heparin-bonding hemagglutinin of a mycobacteria and a method for preparing the sequence chemically and enzymatically. In the method, the sequence is produced in advance as a recombination type that is not methylated and then methylated in post-translational modification. Further, the invention relates to a recombination tool, a vector and a host cell for enzymatic post-translation methylation of the recombination HBHA. The immunogenic composition containing the methylated native or recombination HBHA is useful for preparing the vaccine against mycobacteria infection.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
The study was designed prospectively. A total of 50 patients with subacromial impingement syndrome according to clinical and MRI findings with shoulder pain for at least 3 months were included in the study. Patients were randomly divided into two groups. The first group (isokinetic exercise group, n = 25) was given isokinetic exercise. The second group(home exercise group, n=25) was given home exercise program. Patients were evaluated before and after treatment and 3 months after the end of treatment. In the evaluation, VAS, Shoulder Pain and Disability Index, Constant Murley Scoring, Shoulder Disability Questionnaire, Health Assessment Questionnaire, Pittsburgh Sleep Quality Index, Humic Norm II isokinetic device were used. At statistically evaluation of data Student T Test and Mann Whitney U tests were used. In qualitative datas comparison Ki-Kare Test was used. Significance was evaluated at the level of p\&lt; 0.05.
The invention relates to a diagnosis method of Alzheimer&#39;s disease based on plasma protein markers and machine learning, belonging to the technical field of disease prediction. Current diagnostic methods for alzheimer&#39;s disease are based primarily on amyloid markers or nuclear magnetic resonance images, detection usually occurring when individuals have significant symptoms and signs. Alzheimer&#39;s disease is hidden from disease, and early symptoms are not easily detected. Aiming at the defects and shortcomings of the existing Alzheimer disease diagnosis method, the method utilizes plasma protein to analyze metabolic changes of patients, and predicts the illness state of the patients through an integrated learning algorithm Catboost. The method can accurately predict early and different development stages of the disease, thereby assisting doctors in timely and accurately performing intervention and treatment on the disease. Compared with amyloid markers and MRI image detection, the method has the characteristics of low cost, no wound and easy acquisition, improves the accuracy and objectivity of Alzheimer disease diagnosis, and is easy to popularize in clinical application.
PROBLEM TO BE SOLVED: To obtain an antimicrobial agent high in dermal safety and superior in storage stability, exhibiting high antibacterial power against Gram-positive bacteria, by making the agent include a specific hydrochalcone derivative as active ingredient. SOLUTION: This antimicrobial agent is obtained by including a hydrochalcone derivative of the formula [R&lt;1&gt; to R&lt;4&gt; are each H or COR (R is a 1-20C alkyl)] as active ingredient [e.g. 1,3-bis(2,4-dihydroxyphenyl)propane]. The derivative of the formula can be obtained, for example, by extraction/ purification from Dioscorea Composita. The amount of the derivative of the formula to be formulated is pref. 0.0005-10.0 wt.% based on the whole amount of this antimicrobial agent. This agent is applicable, pref. to Propionibacterium acnes and the like, being hopeful of the prevention/treatment of cutaneous bacterial infectious diseases caused by Gram-positive bacteria, especially pimple.
PURPOSE: To prepare a new indenesulfonamide derivative having antineoplastic activity and useful, particularly, for the treatment of solid cancer and solid tumors as antitumor agents suitable also to oral administration.  
     CONSTITUTION: A compd. of formula I (A is formulae II to III; R 1  is a halogen or H; R 2  is a halogen or CF 3 ) or the pharmaceutically acceptable salts or solvates thereof such as N-[[(4-chlorophenyl)amino]carbonyl]indene-5- sulfonamide. The compd. is produced by bringing a compd. of formula IV to react with a compd. of formula V in the presence of an acid supplemental agent or bringing a compd. of formula VI to react with a compd. of formula VII or bringing a reaction product of a compd. of formula VII with a compd. of the formula XCOOR 3  (X is Br or Cl; R 3  is a 1-3C alkyl) to react with a compd. of formula VI. Furthermore, the compd. is useful, particularly for the treatment of solid cancer in the overium, large cell lung, stomach, pancrea, prostate, nephrocyte, nipple, colon, small cell lung, melanoma, head, neck, or the like and solid tumors including sarcomas such as Kaposi&#39;s sarcoma and rhabdomyosarcoma. 
     COPYRIGHT: (C)1993,JPO
NEW MATERIAL:A ketene-S,N-acetal expressed by formula I (R1 is H, halogen, lower alkyl, lower alkoxyl, trifluoromethyl, trifluoromethoxyl, lower alkylthio, etc.; R2 is 1-8C alkyl, haloalkyl, allyl propargyl, alkoxyalkyl, etc.; A is N or CH). EXAMPLE:2-(1H-Imidazol-1-yl)-3-phenylamino-3-n-propylthioacrylonitrile. USE:Useful as an agricultural and horticultural germicide and further germicide as a wood preservative and antifungal agent, and effective for controlling blights such as blast of rice plants, powdery mildew of wheat, etc. and effective for fungi of the genus Candida, athlete&#39;s foot and trichophytes, etc. PREPARATION:An isothiocyanate expressed by formula II is reacted with an azole expressed by formula III in the presence of a base, and the resultant reaction product is without isolation reacted with a halide expressed by formula IV(Z is halogen) to afford the aimed compound expressed by formula I .
PURPOSE:A prolonged release type cefadroxil pharmaceutical, prepared by incorporating a cefadroxil pharmaceutical disintegrable in the stomach with an enteric cefadroxil pharmaceutical, having prolonged action on blood concentration without delay in the initial concentration by the oral administration, and useful as an antimicrobial agent. CONSTITUTION:A prolonged release type pharmaceutical prepared by incorporating (A) a cefadroxil pharmaceutical disintegrable in the stomach with (B) an enteric cefadroxil pharmaceutical. The mixing potency ratio is preferably (30- 50):(70-50). The cefadroxil pharmaceutical disintegrable in the stomach (A) is preferably fine particles or granules disintegrable in the stomach, and the enteric cefadroxil pharmaceutical (B) is perferably fine particles or granules obtained by coating the pharmaceutical disintegralbe in the stomach (A) with an enteric film substance, e.g. &#39;&#39;Eudragit&#39;&#39; or carboxymethyl ethyl cellulose. The resultant pharmaceutical maintains the blood concentration at the time of administration for a long time without delay in the initial concentration.
PURPOSE:The titled composition for raising absorption of a remedy for astham in blood and for improving durability of action time, obtained by blending the remedy for asthma with a phospholipid, collagen, cyclodextrin, etc. CONSTITUTION:A composition for remedying bronchial asthma comprising a remedy for asthma and at least one selected from a phospholipid (e.g., phosphatidyl choline), collagen and cyclodextrin. Collagen is albuminoid mainly comprising skin, bone, tendon, gristle or bonded tissue of young bovine, etc., and cyclodextrin is a non-reducing sugar wherein D-glucose is circularly bonded. Addition of these compounds raises absorption of the remedy for asthma, especially absorption from exodermis, has prolonging effect on durability of medicinal effects, reduces a does and lessens times of administration. The amount of these compounds blended is &gt;=5pts.wt. calculated as the phospholipid alone or total amounts based on 100pts.wt. remedy for asthma.
PURPOSE: An antifungal composition containing liquid obtained from a vegetable with soft rot is provided to ensure high antifungal activity without harm to human body. CONSTITUTION: An antifungal composition contains liquid as an active ingredient, obtained from a vegetable with soft rot. The bacteria causing soft rot include Pseudomonas or Bacillus. The vegetable is Brassica oleracea. A therapeutic agent for athlete&#39;s foot contains the liquid as an active ingredient. A method for preventing fungus comprises a step of treating the liquid to fungi to be removed.
Disclosed is a composition which can accelerate the production of adiponectin, is not problematic in terms of safety issues such as side effects or toxicity, and can be orally administered. The adiponectin production accelerating composition has the effect of accelerating adiponectin production, contains salmon milt extract, brewer&#39;s yeast extract, avian collagen and mineral containing yeast. It is preferable that the salmon milt extract contains low-molecular components broken up as far as olignucleotides and oligopeptides by enzyme treating salmon milt. It is preferable that the brewer&#39;s yeast extract contains 50-80% RNA. It is preferable that the mineral containing yeast contains 0.01-0.02% selenium, 0.3-0.5% copper and 2-3% zinc in dry yeast. Furthermore, it is preferable that 16-17 parts by mass of the brewer&#39;s yeast extract, 33-34 parts by mass of the avian collagen, and 22-23 parts by mass of the mineral containing yeast are included per 100 parts by mass of the salmon milt extract.
PURPOSE: To obtain a safe bathing agent containing an extract of sake lees by-produced on the production of Japanese sake (rice wine) or mirin (glutinous rice wine), and having a warm bathing effect, a moisture-retaining effect, a beautifully whitening effect, etc. CONSTITUTION: This bathing agent contains an extract produced by extracting sake lees by-produced on the production of a Japanese sake or a sweet sake with an alcoholic solvent (e.g. ethanol). The sake extract plentifully contains inorganic ingredients, amino acids, peptides, proteins, etc., and further contains an enzymatic activity-inhibiting substance such as tyrosinase inhibitor. The tyrosinase inhibitor activity is effective for preventing the deposition of melanin pigment, and has a beautifully whitening effect. The inorganic ingredient is the active ingredient of hot spring, and has effects such as a heat-insulating action, a blood circulation-stimulating action, the alleviation of the syndromes of rheumatism, neuralgia, women&#39;s diseases, etc. The amino acids improve the water-retaining capacity of corneum, and give moisture to skin. A large amount of the sake lees can thus effectively be utilized, and can reduce pollutions and excessive cost load accompanied by the disposal of the sake lees.
The present invention relates to a Neisser&#39;s coccus vaccine composite, the preparation of the composite and the application of the composite in medicine. More specifically, the present invention relates to a method of producing a novel engineered meningococcus strain which is more suitable for the production of the adventitial vesicle (or blain) vaccine of Neisser&#39;s coccus, particularly meningococci. Based on the application of the novel LOS subunit or meningococcal adventitial vesicle (or blain) vaccine, a favorable method and a vaccine product are also described, and the LOS subunit or meningococcal adventitial vesicle (or blain) vaccine can be more safely and effectively used on a human subject. Specifically, the present invention describes gene-downregulated combinations, such as PorA and OpA, PorA and OpC, OpA and OpC, PorA and OpA and OpC. Alternatively or additionally, the present invention indicates that lgtB&lt;-&gt; is the optimal mutation which ensures that L3 and / or L2 LOS can be effectively and safely used in the Neisser&#39;s coccus vaccine composite. The present invention also describes a blain vaccine coming from the lgtB&lt;-&gt; and the meningococcal mutant strain and a favorable method of preparing a blain preparation, and wherein, the LOS is maintained as an important antigen.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an antiallergic agent acting on an immune system, being effective for prevention and amelioration of allergic symptom, and having high safety, to provide a method for producing the antiallergic agent, and to provide a composition for eating and drinking, and a composition for medicine or an animal medicine containing the antiallergic agent.  &lt;P&gt;SOLUTION: The antiallergic agent contains an alcohol-insoluble fraction of a digest of Vigna angularis by Aspergillus oryzae as an active ingredient. Preferably, the antiallergic agent is used for an eating and drinking material, a medicine or an animal medicine. The method for producing the antiallergic agent includes allowing the Vigna angularis to be digested by the Aspergillus oryzae, and adding an alcohol to an aqueous solution of the digest to provide a solid component as the alcohol-insoluble fraction. The composition for eating and drinking, for the medicine or for the animal medicine contains the antiallergic agent.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To prepare a warm sense-giving cosmetic which gives a sufficient warm sense, when brought into contact with the skin, has excellent temporal stability, and especially does not cause temporal discoloration, the expansion of a container, and the like.  &lt;P&gt;SOLUTION: This warm sense-giving cosmetic giving the warm sense, when brought into contact with the skin, and having creamy or gel-like viscosity is characterized by containing zeolite adjusted to a pH value of ≤10 and a polyethylene glycol containing polyethylene glycol liquid at the ordinary temperature and having an average mol. wt. of ≥1,200, containing the polyethylene glycol liquid at the ordinary temperature in an amount of ≥60 wt. % based on the total amount of the cosmetic, and substantially not containing water and a polyhydric alcohol except the polyethylene glycol.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
A medical device information technology (&#34;IT&#34;) data transfer system in one embodiment includes a cluster domain, an external domain and an interface domain. Equipment belonging to the cluster domain may communicate in real time such that availability, safety, security, reliable integrity and performance are guaranteed. The external domain includes equipment not enabled for direct inclusion in the cluster domain, and may include equipment for external information systems, presentation equipment, personal computer equipment, shared medical equipment and bedside medical equipment. The interface domain enables external domain equipment to communicate with cluster equipment in a bidirectional manner. Communication may be via certain access nodes in the cluster. The access nodes enable exchange of information between the open external domain and the closed and private cluster domain.
PROBLEM TO BE SOLVED: To obtain an easily administrable solid preparation of H2 -blocker having reduced bitterness without using both a complicated production method having many steps, and a solvent by adding a specific sugar alcohol. SOLUTION: This easily administrable solid preparation of H2 -blocker is obtained by adding &gt;=25 pts.wt. sugar alcohol such as xylitol, sorbitol, mannitol and erythritol having &lt;=-60kJ/kg, preferably &lt;=-100kJ/kg heat of dissolution to 1 pt.wt. H2 -blocker so as to be 50-99.9% of the total amount of the medicine. The sugar alcohol regardless of which has about same or less sweetness as sugar or dextrose hardly improving the bitterness, shows effects improving the bitterness of the H2 -blocker. Moreover, the addition of 1-menthol can further improve the improving effect of the bitterness. This solid medicine is readily dissolved and collapsed in the mouth, hardly provides rough feeling and easily administered while providing refrigerant with smooth feeling.  Further, the medicine can be formed into a better administration shape because hardly requiring the ingestion of large amount of water.
NEW MATERIAL:An optically active compound shown by the formula I (R1 is H or CH3; R2 is H or 1-4C alkyl; absolute configuration of 1 position is either R configuration or S configuration) or its acid addition salt. EXAMPLE:(R)-1-Cyclohexyl-2-phenylethylamine. USE:A drug, its intermediate or an analgesic. Since this compound has improved analgesic action is an optical isomer having approximately 100% optical purity, it has more enhanced pharmaceutical action than a racemic modification, has alleviated side effects and is useful as an analgesic for pain of various cancers, gastric ulcer, duodenal ulcer, renal calculus, urinary calculus, arteritis obliterans, etc., or pain after operation or pain caused by a tool for examining the stomach, ureter, urinary bladder, etc. PREPARATION:An optically active 2-phenylethylamine compound shown by the formula II (1&#39; position = 1 position) is subjected to hydrogenolysis in a solvent such as glacial acetic acid, etc., in the presence of a catalyst such as Pd/C, etc., at 5-100 atm. hydrogen pressure at 15-30 deg.C for 12-24hr to give a compound shown by the formula I wherein R2 is H.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a gene exasperating the production of amyloid-β protein, to provide the protein, and to provide their uses.  &lt;P&gt;SOLUTION: The gene exasperating the production of the amyloid-β protein. The protein or its salt encoded in the gene. An antibody against the protein. A diagnostic agent or medicine containing the antibody. A method for screening a compound effective for treating Alzheimer&#39;s disease with the protein or the like. A kit used for screening the compound effective for treating Alzheimer&#39;s disease, and containing the protein or the like.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
NEW MATERIAL:A compound of formula I (R&lt;1&gt; is H or a protecting group of the carboxyl group; R&lt;2&gt; is aryl which may be substituted; R&lt;3&gt; is halogen or cyclic amino which may be substituted) and a salt thereof. EXAMPLE:Ethyl 2-( 2,6-dichloro-5-fluoronicotinoyl )-3-( 2,4-difluorophenylamino ) acrylate. USE:An antimicrobial agent and an intermediate therefor, capable of exhibiting powerful antimicrobial action on Gram-positive and Gram-negative bacteria, particularly antibiotic-resistant germs and giving a high concentration in blood by oral and parenteral administration, and having high safety. PREPARATION:A compound of formula II is reacted with N,N-dimethylformamide dimethyl acetal, etc. according to the reaction formulas to give a reaction product, which is then reacted with an amine of the formula R&lt;2&gt;-NH2 to afford a compound of formula II or a salt thereof. The resultant compound of formula II or salt thereof is subjected to the ring closure reaction in the presence or absence of a base to give the aimed compound of formula I.
575,827. Clarifying foul liquids. TRIGGS, W. W. (Dorr Co.) Aug. 23, 1944, No. 16091. [Classes 46 and 111] Apparatus for the clarification of polluted liquids comprises a tank having partitioning means the lower edge of which is spaced from the bottom of the tank, so that the tank is divided into two communicating compartments, each compartment having means for the supply and withdrawal of liquid, means being provided for delivering into the second compartment liquid that has been withdrawn from the first compartment and submitted to an additional treatment, and means being provided for withdrawing sediment from the bottom of the tank. In the construction indicated in Figs. 1 and 2, a tank 10 is divided into two compartments 22, 23 by a partition 19 which terminates above the bottom of the tank to leave a space for passage of an endless conveyer 40 provided with scrapers 47 for delivering sediment to a sump 13. Liquid to be treated enters compartment 22 by a feed pipe 6 and is distributed by a launder 25 and baffle 26. At the other end of the compartment is a launder 32 from which liquid flows through pipe 73 to a biologic trickling filter 70. Liquid also flows to the filter through pipe 75 from the outlet&#39;37 of the compartment 23. The filtered liquid is pumped through pipe 82 and valve-controlled pipes 83,84 to the feed pipe 6 and to a launder 30 of the compartment 23. Scum is removed through a slotted trough 58 provided with an adjusting handle 60. In a modification the filter is above the level of the top of the tank and the pump supplies the liquid to the filter. Fig. 7 shows an arrangement in which two filters are used. Liquid from launder 30 is led by a pipe 106 to a well 107 from which it is pumped through pipes 108, 110 to a filter 100. The filtered liquid flows through pipes 101, 102, 103, pipe 103 communicating through pipe 104 with a well 105 from which liquid is pumped to the filter 120. The filtered liquid flows to launder 32. The quantity of liquid supplied to the launder 32 may be larger than that overflowing past the weir 36 whereby a back flow of liquid occurs along the bottom of the tank from compartment 23 to compartment 22, and this facilitates the work of the scrapers 47 on the endless conveyer 40.
Activation of the c-fos promoter and the serum response element (SRE) in androgen independent cancer cells has been demonstrated. In androgen dependent cells, direct activation of protein kinase C (PKC) or serum response factor (SRF) activated the c-fos promoter or SRE and caused androgen independent expression of an androgen target promoter. The highly specific PKC inhibitor chelerythrine selectively killed androgen independent cells. Expression of mutant SRF cDNA&#39;s inhibited activation of the SRE in prostate cancer cells. These reagents demonstrate the feasibility of both chemotherapy and gene therapy in interfering with intracellular pathways on which androgen independent cells are dependent; i.e. a strategy is outlined for treating hormone independent cancer in which the PKC-SRE pathway is disrupted by either chemotherapy or gene therapy.